F0806
Factor IX human
aqueous glycerol solution, ≥145 units/mg protein
Synonyme(s) :
Christmas factor, Plasma thromboplastin component
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
100 μG
313.00 CHF
A propos de cet article
Form:
aqueous glycerol solution
Biological source:
human
Mol wt:
55 kDa
Passer à
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider1 of 4
Cet article | |||
|---|---|---|---|
| technique(s) ligand binding assay: suitable | technique(s) - | technique(s) - | technique(s) ligand binding assay: suitable |
| biological source human | biological source - | biological source - | biological source human |
| mol wt 55 kDa | mol wt - | mol wt - | mol wt - |
| form aqueous glycerol solution | form liquid | form liquid | form aqueous glycerol solution |
| shipped in wet ice | shipped in wet ice | shipped in wet ice | shipped in wet ice |
| specific activity ≥145 units/mg protein | specific activity ≥20 units/mg protein | specific activity ≥85 units/mg protein (clotting assay) | specific activity ≥25 units/mg protein |
General description
Factor IX is a 55 kDa single chain vitamin K-dependent plasma zymogen which plays a key role in the intrinsic and extrinsic blood coagulation systems.
Application
Factor IX is plasma zymogen key to blood coagulation systems. It has been used in studies of portal vein thrombosis (PVT) in hepatocellular carcinoma (HCC). It has been found that abnormalities in factor IX contribute to PVT in HCC patients. Additionally, it has been used in studies of changes in the coagulation system in patients with inflammatory bowel disease (IBD).
Physical form
Aqueous solution containing 50% (v/v) glycerol
Other Notes
One unit is equivalent to the Factor IX activity in 1.0 mL of normal human plasma at pH 7.4 at 37 °C.
View this factors role in the Coagulation Cascade
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Classe de stockage
10 - Combustible liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Uri Martinowitz et al.
Thrombosis research, 131 Suppl 2, S11-S14 (2013-03-30)
Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) is a novel recombinant albumin fusion protein designed to extend the half-life of recombinant factor IX (rFIX), which is used in the management of hemophilia B. Clinical evaluation of rIX-FP
Elena Santagostino
Thrombosis research, 131 Suppl 2, S7-10 (2013-03-30)
Hemophilia B is a severe bleeding disorder that is characterized by a deficiency or dysfunction of coagulation factor IX (FIX). Replacement therapy using recombinant or plasma-derived FIX is available, but the relatively short half-life of FIX (approximately 18 hours) necessitates
Priya Verghese et al.
Pediatric nephrology (Berlin, Germany), 28(5), 823-826 (2013-02-06)
Nephrotic syndrome (NS) is a recognized complication of immune tolerance induction (ITI) therapy, a treatment strategy used to treat inhibitors in patients with hemophilia B receiving factor IX concentrate. We present a 4-year-old boy with hemophilia B and an inhibitor
[Hemophilia].
Midori Shima
[Rinsho ketsueki] The Japanese journal of clinical hematology, 54(2), 189-197 (2013-03-09)
Brian R Branchford et al.
Current opinion in pediatrics, 25(1), 23-30 (2013-01-01)
Disorders of hemostasis such as hemophilia, von Willebrand disease (VWD), and other clotting protein deficiencies lead to significant morbidity in the pediatric population. Because of the limitations of current treatment options, novel therapies are being developed, many of which are
Contenu apparenté
Instructions
Numéro d'article de commerce international
| Référence | GTIN |
|---|---|
| F0806-100UG | 04061838031044 |
Active Filters
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique